Introduction: TNF inhibitors have been used to treat inflammatory bowel diseases for the past 2 decades. These medications act to control acute flares as well as reach and maintain remission. However, side effects remain a large concern. Physicians should maintain a low threshold of suspicion for both opportunistic infection and malignancy, particularly lymphoma and leukemia, in their patients taking TNF inhibitors. Case: A 31-year-old 19 weeks pregnant female (G1P0, GA 19w0d) with Crohn’s disease presented with one month of right lower quadrant pain, fever, chills and fatigue. She had an incision and drainage performed for right thigh folliculitis 6 weeks before, and since then had continued pain in the right inguinal and lower quadrant area. She has been on adalimumab and azathioprine since 2015 with no recent flare ups; her last dose of adalimumab was given just before this admission. On admission, patient was febrile, tachypneic, and tachycardic, with leukocytosis. Given concern for sepsis in the setting of pregnancy, she was admitted to ICU and started on vancomycin and ampicillin-sulbactam for broad coverage. Imaging revealed extensive retroperitoneal lymphadenopathy along the right iliac chain and right inguinal region. She underwent an excisional biopsy from right inguinal lymph nodes. While final pathology results were pending, respiratory symptoms worsened, leading to an increased oxygen requirement. Chest CT showed progressive patchy ground glass opacities. Azithromycin and steroids were started, with pentamidine to cover possible Pneumocystis carinii pneumonia (PCP). On hospital day 15, the patient had a spontaneous vaginal delivery of a nonviable fetus. She experienced multi-system organ failure in following days, requiring vasopressor support, intubation, mechanical ventilation, and continuous renal replacement therapy due to severe metabolic acidosis. Antibiotics were broadened to vancomycin, meropenem, clindamycin, micafungin, azithromycin and pentamidine without meaningful clinical improvement. Multiple cultures, including a bronchoalveolar lavage, showed no pathogen. Final pathology revealed ALK-positive anaplastic large-cell lymphoma, a type of non-Hodgkin lymphoma, and the patient was started on chemotherapy with cyclophosphamide and doxorubicin. She had drastic clinical improvement following the first dose. She was then weaned off vasopressors and extubated. Antibiotics were discontinued, except atovaquone for PCP prophylaxis, and the patient was discharged on hospital day 26. Discussion: It is hypothesized that T cell dysfunction is involved in the pathogenesis of Crohn’s disease and studies have reported that patients with chronic inflammatory disorders might have an increased baseline risk of lymphomas regardless of TNF antagonist treatments. As physicians, we maintain high suspicion for opportunistic infections in IBD patients on TNF inhibitors presenting with signs of a systemic inflammatory response. However, clinical features associated with sepsis– such as fever, tachycardia, tachypnea, and leukocytosis– can indicate malignancy as well. Some lymphomas cause inflammatory responses that respond to chemotherapy. This case emphasizes the importance of avoiding singular focus on opportunistic infection in IBD patients.
Read full abstract